Cargando…
Evaluation of (177)Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors
BACKGROUND: (177)Lu peptide receptor radionuclide therapy (PRRT) is a recently approved therapy in Spain that has been demonstrated to be a well-tolerated therapy for positive somatostatin receptor advanced gastroenteropancreatic neuroendocrine tumors. AIM: To determine the impact of PRRT on quality...
Autores principales: | Abou Jokh Casas, Estephany, Pubul Núñez, Virginia, Anido-Herranz, Urbano, del Carmen Mallón Araujo, María, del Carmen Pombo Pasín, Maria, Garrido Pumar, Miguel, Cabezas Agrícola, José Manuel, Cameselle-Teijeiro, José Manuel, Hilal, Ashraf, Ruibal Morell, Álvaro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152518/ https://www.ncbi.nlm.nih.gov/pubmed/32308351 http://dx.doi.org/10.3748/wjg.v26.i13.1513 |
Ejemplares similares
-
Added-value of molecular imaging in myocardial metastasis of an ileal neuroendocrine tumour treated with peptide receptor radionuclide therapy: a case report
por: Mallón Araujo, María Del Carmen, et al.
Publicado: (2021) -
Enhanced quantitative method for the diagnosis of grade 1 cardiac amyloidosis in (99)mTc-DPD scintigraphy
por: Mallón Araujo, María del Carmen, et al.
Publicado: (2022) -
Lutetium Lu-177 Dotatate Flare Reaction
por: Salner, Andrew L., et al.
Publicado: (2020) -
Efficacy of [(177)Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study
por: Mitjavila, Mercedes, et al.
Publicado: (2023) -
OR08-04 Paradigm Shift In SDHAF2-Related Familial Paraganglioma Syndrome
por: Fernandez-Pombo, Antia, et al.
Publicado: (2023)